TY - JOUR
T1 - 17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex
AU - Harrison, David E.
AU - Strong, Randy
AU - Reifsnyder, Peter
AU - Kumar, Navasuja
AU - Fernandez, Elizabeth
AU - Flurkey, Kevin
AU - Javors, Martin A.
AU - Lopez-Cruzan, Marisa
AU - Macchiarini, Francesca
AU - Nelson, James F.
AU - Bitto, Alessandro
AU - Sindler, Amy L.
AU - Cortopassi, Gino
AU - Kavanagh, Kylie
AU - Leng, Lin
AU - Bucala, Richard
AU - Rosenthal, Nadia
AU - Salmon, Adam
AU - Stearns, Timothy M.
AU - Bogue, Molly
AU - Miller, Richard A.
N1 - Publisher Copyright:
© 2021 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
PY - 2021/5
Y1 - 2021/5
N2 - In genetically heterogeneous mice produced by the CByB6F1 x C3D2F1 cross, the “non-feminizing” estrogen, 17-α-estradiol (17aE2), extended median male lifespan by 19% (p < 0.0001, log-rank test) and 11% (p = 0.007) when fed at 14.4 ppm starting at 16 and 20 months, respectively. 90th percentile lifespans were extended 7% (p = 0.004, Wang–Allison test) and 5% (p = 0.17). Body weights were reduced about 20% after starting the 17aE2 diets. Four other interventions were tested in males and females: nicotinamide riboside, candesartan cilexetil, geranylgeranylacetone, and MIF098. Despite some data suggesting that nicotinamide riboside would be effective, neither it nor the other three increased lifespans significantly at the doses tested. The 17aE2 results confirm and extend our original reports, with very similar results when started at 16 months compared with mice started at 10 months of age in a prior study. The consistently large lifespan benefit in males, even when treatment is started late in life, may provide information on sex-specific aspects of aging.
AB - In genetically heterogeneous mice produced by the CByB6F1 x C3D2F1 cross, the “non-feminizing” estrogen, 17-α-estradiol (17aE2), extended median male lifespan by 19% (p < 0.0001, log-rank test) and 11% (p = 0.007) when fed at 14.4 ppm starting at 16 and 20 months, respectively. 90th percentile lifespans were extended 7% (p = 0.004, Wang–Allison test) and 5% (p = 0.17). Body weights were reduced about 20% after starting the 17aE2 diets. Four other interventions were tested in males and females: nicotinamide riboside, candesartan cilexetil, geranylgeranylacetone, and MIF098. Despite some data suggesting that nicotinamide riboside would be effective, neither it nor the other three increased lifespans significantly at the doses tested. The 17aE2 results confirm and extend our original reports, with very similar results when started at 16 months compared with mice started at 10 months of age in a prior study. The consistently large lifespan benefit in males, even when treatment is started late in life, may provide information on sex-specific aspects of aging.
KW - 17-α-estradiol
KW - candesartan cilexetil
KW - geranylgeranylacetone
KW - heterogeneous mice
KW - lifespan
KW - macrophage migration inhibitory factor
KW - nicotinamide riboside
UR - http://www.scopus.com/inward/record.url?scp=85103421691&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103421691&partnerID=8YFLogxK
U2 - 10.1111/acel.13328
DO - 10.1111/acel.13328
M3 - Article
C2 - 33788371
AN - SCOPUS:85103421691
SN - 1474-9718
VL - 20
JO - Aging cell
JF - Aging cell
IS - 5
M1 - e13328
ER -